Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Biotech firm Gilead Sciences has announced plans to voluntarily withdraw the US accelerated approval for Trodelvy ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Perrigo Company (PRGO – Research Report) today and set a price target of ...

DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Schrödinger is trading near 52-week lows, prompting a fresh analysis. Learn more about SDGR stock and the complexities of its ...